Thousands of people with debilitating hayfever to benefit from new drug
Betula verrucosa, sold under the brand name Itulazax 12 SQ-Bet and made by Alk-Abello, is an under-the-tongue immunotherapy tablet that contains birch pollen extract.
The drug trains the immune system to tolerate tree pollen over three years of daily use.
It has been recommended as an option on the NHS for people whose hayfever symptoms persist even after taking antihistamines or using nasal sprays, by the National Institute for Health and Care Excellence (Nice).
Severe tree pollen allergies can cause debilitating symptoms for some people during the spring and summer months, including fatigue, breathing difficulties, inflamed sinuses, itchy, watery eyes, and vision changes.
Trials show the tablet can significantly reduce the symptoms of severe hayfever by changing how the body responds to allergens.
The immunotherapy works by gradually increasing the body's tolerance to tree pollen through controlled daily exposure to small amounts of pollen.
Before being given the tablets, patients will require skin prick or blood tests to confirm an allergy to birch tree pollen.
Nice estimates that about 27,000 people in England are expected to benefit from the recommendation.
Helen Knight, director of medicines evaluation at Nice, said: 'This treatment will help improve people's quality of life.
'Severe tree pollen allergies trap people indoors during beautiful weather and disrupt their work, education and family life.
'The daily tablet offers genuine long-term relief rather than just managing symptoms.'
According to Allergy UK, birch pollen allergy is estimated to affect about 25% of hayfever sufferers.
Amena Warner, head of clinical services at Allergy UK, said: 'Many people don't realise how awful it is having an itchy, runny nose, sneezing episodes or itchy, irritated eyes in the pollen season.
'We frequently hear from people who avoid time outdoors, keep doors and windows shut, check pollen counts and try and minimise any exposure, which takes a significant toll on their physical and emotional wellbeing.
'Nice's recommendation is so important because it provides a genuine opportunity for people to manage the root cause of their pollen allergy, offering the chance to break free from this burden and enjoy a better quality of life.'
Emil Stage Olsen, general manager UK and Republic of Ireland at ALK, added: 'We welcome this positive Nice recommendation, which is another meaningful advancement for the UK allergy community.
'Our focus is now on working closely with the NHS to ensure eligible patients can benefit from this first-in-class immunotherapy.'
The NHS in England will provide the treatment within three months of Nice publishing its final guidance.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 hours ago
- Medscape
Weight-Loss Drug Demand Risks Overwhelming Pharmacies
Unprecedented demand for weight-loss medication risks going far beyond what is clinically deliverable, the National Pharmacy Association (NPA) has warned. A survey of over 2000 adults for the NPA found that more than 1 in 5 adults had attempted to access weight-loss treatments — either online or in person — in the past year. Among 16- to 34-year-olds, the figure rose to more than 1 in 3. In contrast, only 7% of adults over 55 had made similar attempts. The NPA said that many people seeking treatment are not clinically eligible. It urged the government to bring forward plans to include pharmacies in the rollout of the NHS weight management-programme. The association said social media had played a major role in fuelling demand, raising concerns that patients could turn to unregulated online suppliers. Tighter Safeguards Needed The NPA called for new regulations to protect patients buying weight-loss medication online, ensuring a two-way consultation and a review of relevant medical records by a qualified prescriber. The survey, carried out by market research firm Savanta, also found that 41% would be willing to access weight-loss treatments through the NHS if these were made available to them. Among 25- to 34-year-olds, the figure rose to 64%. The NPA said the findings highlight booming demand for both private and NHS weight-loss services. Eligibility Criteria Remain Strict According to guidance from the National Institute for Health and Care Excellence, patients must meet strict clinical criteria to be prescribed drugs such as Mounjaro and Wegovy. Pharmacy-prescribed patients typically need a BMI of at least 35 and at least one weight-related comorbidity. Wegovy may be offered to people with a BMI of 30-34.9 who meet the criteria for referral to specialist overweight and obesity management services. Currently, the NHS offers Mounjaro only to those with a BMI of over 40 and at least four comorbidities. GP Services Already Under Strain Last month, after Mounjaro became available at GP surgeries in England, Royal College of General Practitioners chair Professor Kamila Hawthorne urged patients not to contact their GP unless they thought they met eligibility criteria. She warned that GPs were already "overburdened" and lacked the workforce to meet additional demand. The NPA estimates that at least 85% of prescriptions for weight-loss medication were handled by pharmacies in April this year. During the launch of the 10-Year Health Plan, Prime Minister Sir Keir Starmer pledged to deliver 'innovative weight-loss services' through pharmacies. However, the NPA noted that no further details have been provided about pharmacy involvement in the NHS rollout of these services. 'Weight-loss jabs are one of the biggest drug innovations this century,' said Olivier Picard, NPA chair. 'But growing demand for weight-loss treatment highlights the need to make sure this is appropriate for those who want it,' he added. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit,' Picard said.
Yahoo
4 hours ago
- Yahoo
Pharmacies warn of unsustainable demand for weight loss medication
The booming demand for weight loss jabs may be unsustainable, pharmacists warn. Many more patients are interested in using weight loss medication than are actually suitable for treatment, according to the National Pharmacy Association (NPA), which represents more than 6,000 independent community pharmacies. Some 21% of people who were interviewed in a NPA-commissioned poll agreed they had attempted to access weight loss treatments in the last year, either online or in person at a pharmacy, rising to 35% of 16 to 34-year-olds. This is compared to only 7% of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'
Yahoo
5 hours ago
- Yahoo
Homelessness charity calls for clearer government strategy to tackle crisis
A homelessness charity has called for greater clarity on the Government's strategy to tackle rising housing insecurity. Alabaré, which supports vulnerable people across the South West and Wales, has warned that more action is needed to prevent homelessness and improve long-term outcomes. The call comes as new figures from the Ministry of Housing, Communities and Local Government reveal that more than 131,000 households were living in temporary accommodation between January and March - a 12 per cent increase on the previous year. Read more People invited to take part in sleepout at Stonehenge for charity Former military leader named as next chairman of homelessness charity Football club to donate bar sales to homelessness charity Alabaré has called for Government action on homelessness. (Image: Alabaré) Andrew Lord, CEO of Alabaré, said: "The rising numbers of people being pushed into poverty and ultimately homelessness are frightening, and we feel it's vital that the government sets out a clear plan, with the support of charities like ours, to turn the corner and make sure those who need the help have access to it." Alabaré provides accommodation and support for people who are homeless or at risk, including veterans, young people and individuals with learning disabilities. The charity also offers emergency and temporary beds for those experiencing mental health crises, along with drop-in services. Mr Lord said: "We'd like to see the Government stick to their commitment of funding for affordable housing and to make sure support services can help people long-term, as well as in times of crisis."
